Profile data is unavailable for this security.
About the company
Cutia Therapeutics is a China-based company mainly engaged in the research and development and manufacture of dermatological biological drugs. The Company is committed to developing comprehensive solutions to meet the diverse needs of patients and consumers in a wide range of dermatological treatment and care markets. The Company is mainly engaged in clinical trials of its core product CU-20401. This product is mainly used to treat submental fat accumulation. The Company conducts its businesses in the domestic market and overseas markets.
- Revenue in HKD (TTM)217.21m
- Net income in HKD-572.76m
- Incorporated2019
- Employees360.00
- LocationCutia Therapeutics436 Heng Feng RoadJingan District, 20/F, Huanzhi BuildingSHANGHAI ChinaCHN
- Websitehttps://www.cutiatx.com/
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
VIVA Biotech Holdings | 2.18bn | -347.36k | 2.08bn | 2.04k | -- | 0.5020 | 8.19 | 0.9559 | -0.0055 | -0.0055 | 1.06 | 1.93 | 0.2603 | 5.26 | 5.18 | 1,049,316.00 | 0.4017 | -1.39 | 0.5601 | -1.68 | 33.66 | 34.81 | 1.54 | -5.44 | 1.46 | 3.19 | 0.2884 | -- | -9.42 | 59.31 | 78.03 | -- | 31.98 | -- |
Golden Throat Holdings Group Co Ltd | 1.10bn | 286.42m | 2.37bn | 860.00 | 8.26 | 1.69 | 7.19 | 2.15 | 0.3874 | 0.3874 | 1.49 | 1.90 | 0.4994 | 3.23 | 4.07 | 1,264,845.00 | 13.01 | 11.00 | 19.26 | 15.63 | 72.29 | 72.79 | 26.06 | 24.67 | 1.93 | 37.74 | 0.2814 | 83.15 | -3.09 | 6.73 | -11.04 | 19.61 | -32.13 | 38.94 |
Cutia Therapeutics | 217.21m | -572.76m | 3.96bn | 360.00 | -- | 3.04 | -- | 18.23 | -1.88 | -1.88 | 0.7136 | 4.26 | 0.1206 | 2.31 | 6.93 | 728,907.80 | -31.81 | -- | -35.82 | -- | 50.33 | -- | -263.68 | -- | 4.82 | -- | 0.1818 | -- | 1,110.83 | -- | -253.30 | -- | -- | -- |
Jiangsu Recbio Technology Co Ltd | 0.00 | -599.19m | 4.12bn | 507.00 | -- | 4.48 | -- | -- | -1.25 | -1.25 | 0.00 | 1.91 | 0.00 | -- | -- | 0.00 | -25.33 | -- | -32.84 | -- | -- | -- | -- | -- | 0.9619 | -- | 0.4548 | -- | -- | -- | 20.86 | -- | -- | -- |
Ocumension Therapeutics | 338.94m | -352.52m | 4.58bn | 477.00 | -- | 1.28 | -- | 13.53 | -0.5379 | -0.5379 | 0.517 | 4.36 | 0.103 | 2.40 | 2.48 | 763,383.40 | -10.71 | -38.78 | -11.55 | -41.47 | 58.29 | 62.30 | -104.01 | -975.82 | 5.00 | -- | 0.0055 | -- | 54.99 | -- | 5.68 | -- | 319.66 | -- |
Beijing Luzhu Biotechnology Co Ltd | 0.00 | -305.78m | 4.87bn | 148.00 | -- | 4.76 | -- | -- | -1.51 | -1.51 | 0.00 | 5.09 | 0.00 | -- | -- | 0.00 | -23.80 | -- | -25.44 | -- | -- | -- | -- | -- | 5.91 | -- | 0.0296 | -- | -- | -- | 65.62 | -- | -- | -- |
Shandong Boan Biotechnology Co Ltd | 786.30m | 67.51m | 4.88bn | 777.00 | 68.72 | 3.05 | 34.08 | 6.21 | 0.1326 | 0.1326 | 1.54 | 2.99 | 0.3069 | 1.10 | 2.60 | 967,157.30 | 2.63 | -- | 3.43 | -- | 74.10 | -- | 8.59 | -- | 1.03 | 4.01 | 0.3369 | -- | 19.80 | -- | 64.02 | -- | -- | -- |
Data as of Nov 01 2024. Currency figures normalised to Cutia Therapeutics's reporting currency: Hong Kong Dollar HKD
Holder | Shares | % Held |
---|---|---|
FIL Investment Management (Hong Kong) Ltd.as of 28 May 2024 | 13.30m | 4.37% |
Harvest Global Investments Ltd.as of 09 Jun 2023 | 7.16m | 2.35% |
FIL Investment Management (Singapore) Ltd.as of 28 May 2024 | 4.14m | 1.36% |
FIL Investments Internationalas of 31 Aug 2024 | 1.81m | 0.59% |
Bosera Asset Management Co., Ltd.as of 30 Jun 2024 | 205.60k | 0.07% |
Huashang Fund Management Co., Ltd.as of 30 Jun 2024 | 67.40k | 0.02% |
Harvest Fund Management Co., Ltd.as of 30 Jun 2024 | 5.40k | 0.00% |
E Fund Management Co., Ltd.as of 30 Jun 2024 | 4.14k | 0.00% |
FIL Investment Advisors (UK) Ltd.as of 31 Oct 2023 | 1.00 | 0.00% |
More ▼
Data from 30 Jun 2024 - 23 Oct 2024Source: FactSet Research Systems Inc.